View Item 

Show simple item record

Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study
dc.contributor.authorPitt, Bertramen_US
dc.contributor.authorLatini, Robertoen_US
dc.contributor.authorMaggioni, Aldo P.en_US
dc.contributor.authorSolomon, Scott D.en_US
dc.contributor.authorSmith, Beverly A.en_US
dc.contributor.authorWright, Melanieen_US
dc.contributor.authorPrescott, Margaret F.en_US
dc.contributor.authorMcMurray, John J.V.en_US
dc.date.accessioned2014-03-05T18:19:14Z
dc.date.available2014-03-05T18:19:14Z
dc.date.issued2011-07en_US
dc.identifier.citationPitt, Bertram; Latini, Roberto; Maggioni, Aldo P.; Solomon, Scott D.; Smith, Beverly A.; Wright, Melanie; Prescott, Margaret F.; McMurray, John J.V. (2011). "Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study." European Journal of Heart Failure 13(7): 755-764. <http://hdl.handle.net/2027.42/106150>en_US
dc.identifier.issn1388-9842en_US
dc.identifier.issn1879-0844en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106150
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherAliskirenen_US
dc.subject.otherB‐Type Natriuretic Peptideen_US
dc.subject.otherMineralocorticoid Receptor Antagonisten_US
dc.subject.otherReninen_US
dc.titleNeurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment studyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelCardiovascular Medicineen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid21467028en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106150/1/ejhfhfr034.pdf
dc.identifier.doi10.1093/eurjhf/hfr034en_US
dc.identifier.sourceEuropean Journal of Heart Failureen_US
dc.identifier.citedreferencePitt B Zannad F Remme WJ Cody R Castaigne A Perez A Palensky J Wittes J The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 1999 341 709 717en_US
dc.identifier.citedreferenceMcMurray JJ Pitt B Latini R Maggioni AP Solomon SD Keefe DL Ford J Verma A Lewsey J Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure Circ Heart Fail 2008 1 17 24en_US
dc.identifier.citedreferenceZannad F McMurray JJ Drexler H Krum H van Veldhuisen DJ Swedberg K Shi H Vincent J Pitt B Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF) Eur J Heart Fail 2010 12 617 622en_US
dc.identifier.citedreferenceZannad F McMurray JJV Krum H van Veldhuisen DJ Swedberg K Shi H Vincent J Drexler H Pocock S Pitt B for the the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF) Study Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 2011 364 11 21en_US
dc.identifier.citedreferenceLakhdar R Al‐Mallah MH Lanfear DE Safety and tolerability of angiotensin‐converting enzyme inhibitor versus the combination of angiotensin‐converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta‐analysis of randomized controlled trials J Card Fail 2008 14 181 188en_US
dc.identifier.citedreferenceDesai AS Swedberg K McMurray JJ Granger CB Yusuf S Young JB Dunlap ME Solomon SD Hainer JW Olofsson B Michelson EL Pfeffer MA CHARM Program Investigators Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program J Am Coll Cardiol 2007 50 1959 1966en_US
dc.identifier.citedreferenceKrum H Massie B Abraham WT Dickstein K Kober L McMurray JJV Desai A Gimpelewicz C Kandra A Reimun B Rattunde H Armbrecht J on behalf of the ATMOSPHERE Investigators Direct renin inhibition in addition to or as an alternative to ACE inhibition in patients with systolic chronic heart failure: rationale and design of the Aliskiren Trial to Minimize Outcomes in Patients with Heart failure (ATMOSPHERE) study Eur J Heart Fail 2011 13 107 114en_US
dc.identifier.citedreferenceCohn JN Tognoni G Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure N Engl J Med 2001 345 1667 1675en_US
dc.identifier.citedreferenceMcMurray JJ Ostergren J Swedberg K Granger CB Held P Michelson EL Olofsson B Yusuf S Pfeffer MA CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function taking angiotensin‐converting‐enzyme inhibitors: the CHARM‐Added trial Lancet 2003 362 767 771en_US
dc.identifier.citedreferencePfeffer MA McMurray JJ Velazquez EJ Rouleau JL Køber L Maggioni AP Solomon SD Swedberg K Van de Werf F White H Leimberger JD Henis M Edwards S Zelenkofske S Sellers MA Califf RM Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 2003 349 1893 1906en_US
dc.identifier.citedreferenceYusuf S Teo KK Pogue J Dyal L Copland I Schumacher H Dagenais G Sleight P Anderson C ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 2008 358 1547 1559en_US
dc.identifier.citedreferencePitt B Remme W Zannad F Neaton J Martinez F Roniker B Bittman R Hurley S Kleiman J Gatlin M Eplerenone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 2003 348 1309 1321en_US
dc.identifier.citedreferenceLatini R Masson S Anand I Salio M Hester A Judd D Barlera S Maggioni AP Tognoni G Cohn JN Val‐HeFT Investigators The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val‐HeFT Eur Heart J 2004 25 292 299en_US
dc.identifier.citedreferenceLatini R Masson S Wong M Barlera S Carretta E Staszewsky L Vago T Maggioni AP Anand IS Tan LB Tognoni G Cohn JN Val‐HeFT Investigators Incremental prognostic value of changes in B‐type natriuretic peptide in heart failure Am J Med 2006 119 70.e23 30en_US
dc.identifier.citedreferenceMasson S Latini R Anand IS Barlera S Angelici L Vago T Tognoni G Cohn JN Val‐HeFT Investigators Prognostic value of changes in N‐terminal pro‐brain natriuretic peptide in Val‐HeFT (Valsartan Heart Failure Trial) J Am Coll Cardiol 2008 52 997 1003en_US
dc.identifier.citedreferenceWeir RA McMurray JJ Puu M Solomon SD Olofsson B Granger CB Yusuf S Michelson EL Swedberg K Pfeffer MA CHARM Investigators Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin‐converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Added trial Eur J Heart Fail 2008 10 157 163en_US
dc.identifier.citedreferenceGranger CB McMurray JJ Using measures of disease progression to determine therapeutic effect: a sirens' song J Am Coll Cardiol 2006 48 434 437en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhfhfr034.pdf
Size:
377.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.